EUPRAXIA PHARMACEUTICALS INC. Stock-Based Compensation
EUPRAXIA PHARMACEUTICALS INC. (EPRX) reported Stock-Based Compensation of $8.76 million for the 12-month period ending 2025-12-31, per its 40-F filed 2026-03-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-03-13
| Period end | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|
| 2025-12-31 | $8.76M 40-F · filed 2026-03-13 |
| 2024-12-31 | $3.22M 40-F · filed 2026-03-13 |
| 2023-12-31 | $1.41M 40-F · filed 2025-03-20 |
| 2022-12-31 | $1.43M 40-F · filed 2024-04-01 |